Daniela W. Peeler
Vice President of Research and Development, Clinical stage biotechnology
Cambridge, MA · (617) 555 0155 · name@example.com · linkedin.com/in/danielawpeeler
Key Qualifications
EXPERIENCE
Twenty two years in drug discovery and early development, eight at vice president level
INDUSTRIES
Clinical stage biotechnology, large pharmaceutical research, academic drug discovery
SPECIALTIES
Small molecule discovery, target validation, translational biology, investigational new drug enabling studies
SYSTEMS
Dotmatics, Benchling, Veeva Vault, SAS, R, Spotfire
CREDENTIALS
Doctor of Philosophy in medicinal chemistry; inventor on eleven granted patents
EDUCATION
Doctor of Philosophy in medicinal chemistry, Bachelor of Science in chemistry
Executive Summary
Vice president of research and development leading small molecule discovery through early clinical proof of concept. Twenty two years in the industry, four development candidates nominated under her leadership and two of them now in phase two. Runs chemistry, biology, translational science and early development as one integrated group of 130 people.
Signature Achievements
- Nominated four development candidates in six years, two of which have completed phase one and moved into phase two.
- Cleared two investigational new drug submissions through the thirty day review with no clinical hold and no partial hold.
- Cut the time from target selection to development candidate from an average of fifty one months to thirty three.
- Built a translational biomarker package that shortened the phase one dose escalation from nine cohorts to five.
- Reduced external discovery spend by 6.2 million dollars a year by moving medicinal chemistry from three vendors to one dedicated partner.
- Named inventor on eleven granted patents covering two clinical stage chemical series.
Professional Experience
Vice President of Research and Development
Charter Bay Therapeutics, Cambridge, MA 2018 to present
Clinical stage company with two clinical programs and four discovery programs, a research budget of 78 million dollars and a staff of 130
- Leads chemistry, biology, translational science, toxicology and early clinical development and sits on the executive committee.
- Owns the portfolio review process that decides which programs advance, which are held and which are stopped.
- Chairs the development candidate nomination committee and signs the package that goes to the board.
- Directs the investigational new drug enabling program including toxicology, chemistry, manufacturing and controls interfaces and the clinical protocol design.
- Presents research strategy and program status to the board four times a year and to investors at scientific update events.
Senior Director of Discovery Biology
Wharf Street Biosciences, Boston, MA 2011 to 2018
Discovery focused company working in inflammation and fibrosis with a research staff of forty
- Led biology for three discovery programs, two of which reached development candidate nomination.
- Built the in vivo pharmacology group from four scientists to seventeen and brought two disease models in house.
- Negotiated three academic research collaborations that produced the starting point for the lead fibrosis series.
- Coauthored nine peer reviewed papers on target biology and mechanism.
Principal Scientist
Longfellow Research Laboratories, Waltham, MA 2003 to 2011
Research site of a large pharmaceutical company covering medicinal chemistry across two therapeutic areas
- Ran a medicinal chemistry team of nine and delivered two clinical candidates as chemistry lead.
- Designed the structure activity relationship strategy for a kinase series that became a licensed asset.
- Mentored fifteen scientists, six of whom now hold director level roles elsewhere.
Licensure and Certification
Member, American Chemical Society
Member, American Association for Cancer Research
Inventor on eleven granted United States patents
Education
Doctor of Philosophy in medicinal chemistry, University of Michigan, 2003
Bachelor of Science in chemistry, Carleton College, 1997
Core Skills
Discovery portfolio leadership · Development candidate selection · Medicinal chemistry strategy · Translational biomarkers · Investigational new drug enabling studies · Research budget ownership · Board and investor presentation · Academic collaboration · Intellectual property strategy · Scientific team building